Naslov
Henoch-Schonlein purpura nephritis in Croatian children: a retrospective study in five tertiary care centers

Autori
Batnozic Varga, Mateja ; Cekada, Nastasia ; Sestan, Mario ; Srsen, Sasa ; Ruzman, Lucija ; Zaninovic, Maja ; Ovuka, Aleksandar ; Ozdanovac, Ivana ; Pecnjak, Marija ; Kifer, Domagoj ; Frkovic, Marijan ; Gagro, Alenka ; Jelusic, Marija

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, prošireni sažetak, znanstveni

Izvornik
Proceedings of the 25th European Paediatric Rheumatology Congress (PReS 2018): Meeting abstracts. Pediatric Rheumatology 2018 ; 16 (Suppl 2) / - , 2018, P040-P040

Skup
The 25th European Paediatric Rheumatology Congress (PReS 2018)

Mjesto i datum
Lisabon, Portugal, 05.09.2018. - 08.09.2018

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
Henoch-Schönlein purpura ; nephritis ; kidney biopsy

Sažetak
Introduction: Henoch-Schönlein purpura nephritis (HSPN) is the most severe complication of Henoch- Schönlein purpura (HSP) that can occur at any time of the disease process and includes isolated microscopic or macroscopic hematuria, mild or heavy proteinuria with or without nephrotic syndrome, renal failure and hypertension. Objectives: To determine a possible prognostic factor for earlier HSPN onset, to explore indications for kidney biopsy according to urine analysis and the correlation between 24-h urinary protein levels and biopsy findings, as well as biopsy findings and patient outcome. Methods: The cross-sectional study included all children with HSPN diagnosed by EULAR/PRES/PRINTO criteria from 2009 to 2017 at 5 tertiary care centres in Croatia. Results: Out of 540 patients diagnosed with HSP, 91 children who developed HSPN (16.85%) were included. The patient population with HSPN included 52 boys (57.14%) and 39 girls (42.86%). Median (range) age of HSP diagnosis was 8 years (1.5-17.5) and from the HSP diagnosis to HSPN onset was 1.5 (0- 60) months. Median (range) follow-up time was 44 (4-167) months. Nephritis was present in 18.68% of cases at the HSP onset. No statistically significant difference or correlation was found between the time of HSP diagnosis to HSPN onset and gender, age, purpura distribution, joint and gastrointestinal involvement. Kidney biopsy was done in 26 patients (28.57%). Among them, 3 patients had isolated persistent hematuria, 3 had isolated proteinuria and 20 patients had both hematuria and proteinuria. Median (range) 24-h urinary protein levels in patients who underwent biopsy was 1.28 (0-7.46) g/dU. The leading indication for biopsy was simultaneous hematuria and proteinuria (p<0.001), while isolated proteinuria was not a determining factor (p=0.592). Isolated hematuria was a statistically significant factor in detecting patients who were not likely to have a biopsy (p<0.001). Biopsy findings were graded with different classifications: 7 with Oxford classification, 6 with Haas, 1 with ISKDC, while 4 were classified simultaneously with Oxford and ISKDC. Only descriptive findings were available for 8 biopsy specimens. No statistically significant difference was found in 24-h urinary protein levels between different biopsy findings. 68% of HSPN patients were treated with corticosteroids out of which 17.6% patients took immunosuppressive or/and antihypertensive drugs in addition to corticosteroids. Most patients had good outcome, with normal physical exam findings and no signs of renal disease in laboratory tests (78%), or with microhematuria and proteinuria <1g/dU (17.6%), while only 4 patients (4.4%) had a more severe outcome with proteinuria >1g/dU. No significant difference was found in patient outcome for different biopsy findings (p=0.214). Conclusion: Simultaneous hematuria and proteinuria was a statistically significant factor for kidney biopsy. However, while isolated proteinuria was not the sole determining factor, excessive levels of 24-h urinary proteins should be taken in consideration. Due to the small number of patients and no uniform classification generally used in grading biopsy findings, a statistically significant difference in regard to outcome could not be confirmed, indicating the need for both in future research.

Izvorni jezik
Engleski

Napomena
Sažetak je objavljen kao suplement časopisu
(indeksiran u CC-u): Pediatric Rheumatology 2018 ;
16 (Suppl 2): 52

POVEZANOST RADA